Europe Latent TB Detection Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Test (Tuberculin Skin Test (TST) and Interferon Gamma Released Assay (IGRA)) and End User (Hospitals, Diagnostic Centers, Laboratories, and Others)
Market Introduction
The Europe latent TB detection market includes the consolidated markets for Germany, France, the United Kingdom, Italy, Spain, and Rest of Europe. Europe occupies a significant position in the global latent TB detection market and is expected to register a robust growth rate over the forecast period. Germany dominated the market for Europe region. The German healthcare authorities and government is engaged in allowing the research institutes and market companies to conduct researches in the country. Such strategies are projected to accelerate the engagement of the country in the development and adoption of innovative techniques to combat respiratory diseases and breathing problems. Respiratory diseases possess a major disease burden in Germany leading to significant mortality rates. According to the World Health Organization (WHO) – Non-Communicable Diseases (NDC) Profile, 2018, chronic respiratory illness accounts for 6% of total mortality rates in Germany. The government of Germany in November 2016 announced its support for the development of new treatments and diagnostic procedures to combat tuberculosis (TB). The country’s Federal Ministry of Education and Research (BMBF) committed EUR 10 million over five years to TB Alliance that is facilitated by the KfW development bank. The increasing incidence of these diseases is likely to account for the hinder the growth of the latent TB detection market in the country. With the rising incidence of COVID-19 in the country, the need for emergency breathing equipment has also remarkably spiked up in the recent times. The market growth in the region is expected due to increasing prevalence of TB and breathing issues witnessed among people. Additionally, strategic action plans implemented by governments to tackle TB are likely to create lucrative environment for the growth of the Europe latent TB detection market.
In case of COVID-19, Europe is highly affected specially France followed by Spain, Italy, and Germany. The European economy is severely affected due to the exponential growth of COVID-19 cases in the region. Countries across Europe are witnessing a resurgence in COVID-19 cases after successfully mitigating outbreaks early in the year. Many countries are declaring more cases each day now than they were during the first wave earlier this year. Lockdowns are being reintroduced in UK, Spain and Italy, and Ireland, as per the European Centre for Disease Prevention and Control (ECDC). Due to the second wave of COVID-19 cases, the government of many countries is working towards scaling up testing capacity, which is restricting the growth of the market. The COVID-19 pandemic and associated response have impacted healthcare services globally, severely disrupting care for many communicable diseases such as tuberculosis TB. Laboratory diagnostic services, considered a cornerstone of any country's capacity to manage TB, are likely to be severely impacted by the COVID-19 pandemic due to re-allocation of resources. In England, compared with 2019, TB notifications decreased by 16.5% during April and by 37.3% during May 2020; the LTBI program was paused in response to COVID-19 in March.
Get more information on this report :
Market Overview and Dynamics
The Europe latent TB detection market is expected to grow from US$ 304.39 million in 2020 to US$ 420.88 million by 2027; it is estimated to grow at a CAGR of 4.7% from 2020 to 2027. Surging advancements in tuberculosis diagnosis is expected to escalate the market. Fluorescent stamping, antigen detection, ELISA, modified culture methods, and antigen preparations are among the advanced procedures practiced for the diagnosis of TB across the region. Manufacturers and researchers are consistently working toward finding new and viable solutions that are based on potent technologies to accurately diagnose TB. For instance, in July 2020, Cepheid, Inc. and The Foundation for Innovative New Diagnostics (FIND) introduced a new drug-resistant tuberculosis-profiling test that provides test results in 90 min. Moreover, the accessibility of blood-based diagnostics in the form of interferon γ release assays (IGRAs) have helped clinicians deliver reliable test results for diagnosing latent TB infection with high specificity and sensitivity. Thus, the consistent advancements in TB diagnosis is likely to be a prevalent trend in the Europe market during the coming years.
Key Market Segments
In terms of test, the interferon gamma released assay (IGRA) segment accounted for the largest share of the Europe latent TB detection market in 2019. In terms of end user, the hospitals segment held a larger market share of the Europe latent TB detection market in 2019.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the Europe latent TB detection market are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Abbott; ARKRAY, Inc.; BD; bioMerieux SA; F. HOFFMANN-LA ROCHE LTD.; Lionex GmbH; Oxford Immunotec Ltd; QIAGEN; and Serum Institute of India Pvt. Ltd.
Reasons to buy report
- To understand the Europe latent TB detection market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for Europe latent TB detection market
- Efficiently plan M&A and partnership deals in Europe latent TB detection market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Europe latent TB detection market
- Obtain market revenue forecast for market by various segments from 2020-2027 in Europe region.
Europe Latent TB Detection Market Segmentation
Europe Latent TB Detection Market - By Test
- Tuberculin Skin Test (TST)
- Interferon Gamma Released Assay (IGRA)
Europe Latent TB Detection Market - By End User
- Hospitals
- Diagnostic Centers
- Laboratories
- Others
Europe Latent TB Detection Market - By Country
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Europe Latent TB Detection Market - Company Profiles
- Abbott
- ARKRAY, Inc.
- BD
- bioMerieux SA
- F. HOFFMANN-LA ROCHE LTD.
- Lionex GmbH
- Oxford Immunotec Ltd
- QIAGEN
- Serum Institute of India Pvt. Ltd.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Latent TB Detection Market – By Test
1.3.2 Europe Latent TB Detection Market – By End User
1.3.3 Europe Latent TB Detection Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Latent TB Detection Market – Market Landscape
4.1 Overview
4.2 Europe PEST Analysis
5. Europe Latent TB Detection Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Tuberculosis
5.1.2 Rising Government Initiatives to Promote Tuberculosis Detection
5.2 Market Restraints
5.2.1 Existance of Multidrug Resistant Tuberculosis (MDR-TB)
5.3 Market Opportunities
5.3.1 Rise of Market in Emerging Economies
5.4 Future Trends
5.4.1 Surging Advancements in Tuberculosis Diagnosis
5.5 Impact Analysis
6. Latent TB Detection Market – Europe Analysis
6.1 Europe Latent TB Detection Market Revenue Forecast and Analysis
7. Europe Latent TB Detection Market Analysis – By Test
7.1 Overview
7.2 Europe Latent TB Detection Market Share, by Test, 2019 and 2027 (%)
7.4 Tuberculin Skin Test (TST)
7.4.1 Overview
7.4.2 Tuberculin Skin Test (TST): Latent TB Detection Market– Revenue and Forecast to 2027 (US$ Million)
7.5 Interferon Gamma Released Assay (IGRA)
7.5.1 Overview
7.5.2 Interferon Gamma Released Assay (IGRA): Latent TB Detection Market– Revenue and Forecast to 2027 (US$ Million)
8. Europe Latent TB Detection Market Analysis – By End User
8.1 Overview
8.2 Europe Latent TB Detection Market Share, by End User, 2019 and 2027 (%)
8.4 Hospitals
8.4.1 Overview
8.4.2 Hospitals: Latent TB Detection Market– Revenue and Forecast to 2027 (US$ Million)
8.5 Diagnostic Centers
8.5.1 Overview
8.5.2 Diagnostic Centers: Latent TB Detection Market– Revenue and Forecast to 2027 (US$ Million)
8.6 Laboratories
8.6.1 Overview
8.6.2 Laboratories: Latent TB Detection Market– Revenue and Forecast to 2027 (US$ Million)
8.7 Others
8.7.1 Overview
8.7.2 Others: Latent TB Detection Market– Revenue and Forecast to 2027 (US$ Million)
9. Europe Latent TB Detection Market Analysis and Forecasts To 2027 – Country Analysis
9.1 Europe: Latent TB Detection Market
9.1.1 Overview
9.1.3 Europe: Latent TB Detection Market, by Country, 2019 & 2027 (%)
9.1.4 Germany: Latent TB Detection Market – Revenue and Forecast to 2027 (USD Million)
9.1.4.1 Germany: Latent TB Detection Market – Revenue and Forecast to 2027 (USD Million)
9.1.4.2 Germany: Latent TB Detection Market, by Test – Revenue and Forecast to 2027 (USD Million)
9.1.4.3 Germany: Latent TB Detection Market, by End User – Revenue and Forecast to 2027 (USD Million)
9.1.5 UK: Latent TB Detection Market – Revenue and Forecast to 2027 (USD Million)
9.1.5.1 UK: Latent TB Detection Market – Revenue and Forecast to 2027 (USD Million)
9.1.5.2 UK: Latent TB Detection Market, by Test – Revenue and Forecast to 2027 (USD Million)
9.1.5.3 UK: Latent TB Detection Market, by End User – Revenue and Forecast to 2027 (USD Million)
9.1.6 France: Latent TB Detection Market – Revenue and Forecast to 2027 (USD Million)
9.1.6.1 France: Latent TB Detection Market – Revenue and Forecast to 2027 (USD Million)
9.1.6.2 France: Latent TB Detection Market, by Test – Revenue and Forecast to 2027 (USD Million)
9.1.6.3 France: Latent TB Detection Market, by End User – Revenue and Forecast to 2027 (USD Million)
9.1.7 Italy: Latent TB Detection Market – Revenue and Forecast to 2027 (USD Million)
9.1.7.1 Italy: Latent TB Detection Market – Revenue and Forecast to 2027 (USD Million)
9.1.7.2 Italy: Latent TB Detection Market, by Test – Revenue and Forecast to 2027 (USD Million)
9.1.7.3 Italy: Latent TB Detection Market, by End User – Revenue and Forecast to 2027 (USD Million)
9.1.8 Spain: Latent TB Detection Market – Revenue and Forecast to 2027 (USD Million)
9.1.8.1 Spain: Latent TB Detection Market – Revenue and Forecast to 2027 (USD Million)
9.1.8.2 Spain: Latent TB Detection Market, by Test – Revenue and Forecast to 2027 (USD Million)
9.1.8.3 Spain: Latent TB Detection Market, by End User – Revenue and Forecast to 2027 (USD Million)
10. Impact of COVID-19 Pandemic on Europe Latent TB Detection Market
10.1 Europe: Impact Assessment Of COVID-19 Pandemic
11. Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 QIAGEN
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 bioMerieux SA
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 F. HOFFMANN-LA ROCHE LTD.
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 BD
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Abbott
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Oxford Immunotec Ltd
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Lionex GmbH
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 ARKRAY, Inc.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Serum Institute of India Pvt. Ltd.
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. Europe Latent TB Detection Market – Revenue, and Forecast to 2027 (US$ Million)
Table 2. Germany: Latent TB Detection Market, by Test – Revenue and Forecast to 2027 (USD Million)
Table 3. Germany: Latent TB Detection Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 4. UK: Latent TB Detection Market, by Test – Revenue and Forecast to 2027 (USD Million)
Table 5. UK: Latent TB Detection Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 6. France: Latent TB Detection Market, by Test – Revenue and Forecast to 2027 (USD Million)
Table 7. France: Latent TB Detection Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 8. Italy: Latent TB Detection Market, by Test – Revenue and Forecast to 2027 (USD Million)
Table 9. Italy: Latent TB Detection Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 10. Spain: Latent TB Detection Market, by Test – Revenue and Forecast to 2027 (USD Million)
Table 11. Spain: Latent TB Detection Market, by End User – Revenue and Forecast to 2027 (USD Million)
Table 12. Organic Developments Done By Companies
Table 13. Inorganic Developments Done By Companies
Table 14. Glossary of Terms
LIST OF FIGURES
Figure 1. Europe Latent TB Detection Market Segmentation
Figure 2. Europe Latent TB Detection Market – By Country
Figure 3. Europe Latent TB Detection Market Overview
Figure 4. Interferon Gamma Released Assay (IGRA) Segment Held Largest Share of Europe Latent TB Detection Market
Figure 5. Germany to Show Remarkable Growth During Forecast Period
Figure 7. Europe PEST Analysis
Figure 8. Europe Latent TB Detection Market Impact Analysis of Drivers and Restraint
Figure 9. Europe Latent TB Detection Market – Revenue Forecast and Analysis
Figure 10. Europe Latent TB Detection Market Share, by Test, 2019 and 2027 (%)
Figure 11. Europe Tuberculin Skin Test (TST): Latent TB Detection Market– Revenue and Forecast to 2027 (US$ Million)
Figure 12. Europe Interferon Gamma Released Assay (IGRA): Latent TB Detection Market– Revenue and Forecast to 2027 (US$ Million)
Figure 13. Europe Latent TB Detection Market Share, by End User, 2019 and 2027 (%)
Figure 14. Europe Hospitals: Latent TB Detection Market– Revenue and Forecast to 2027 (US$ Million)
Figure 15. Europe Diagnostic Centers: Latent TB Detection Market– Revenue and Forecast to 2027 (US$ Million)
Figure 16. Europe Laboratories: Latent TB Detection Market– Revenue and Forecast to 2027 (US$ Million)
Figure 17. Europe Others: Latent TB Detection Market– Revenue and Forecast to 2027 (US$ Million)
Figure 18. Europe: Latent TB Detection Market, by Key Country – Revenue (2019) (USD Million)
Figure 19. Europe: Latent TB Detection Market, by Country, 2019 & 2027 (%)
Figure 20. Germany: Latent TB Detection Market – Revenue and Forecast to 2027 (USD Million)
Figure 21. UK: Latent TB Detection Market – Revenue and Forecast to 2027 (USD Million)
Figure 22. France: Latent TB Detection Market – Revenue and Forecast to 2027 (USD Million)
Figure 23. Italy: Latent TB Detection Market – Revenue and Forecast to 2027 (USD Million)
Figure 24. Spain: Latent TB Detection Market – Revenue and Forecast to 2027 (USD Million)
Figure 25. Impact of COVID-19 Pandemic in European Country Markets
- Abbott
- ARKRAY, Inc.
- BD
- bioMerieux SA
- F. HOFFMANN-LA ROCHE LTD.
- Lionex GmbH
- Oxford Immunotec Ltd
- QIAGEN
- Serum Institute of India Pvt. Ltd.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe latent TB detection market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Europe latent TB detection market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the latent TB detection market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution